Intratumoral delivery of and Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) induces local and systemic antitumor CD8+ T-cell activation and tumor kill. The effector response however, is transient and is rapidly countered by CD4+ Foxp3+ Tsuppressor cell expansion. To determine whether depletion of the pre-existing T-suppressor cell pool prior to treatment could diminish post-therapy regulatory cell resurgence, FVBneuN mice bearing advanced spontaneous mammary tumors were treated with cyclophosphamide (CY) one day before IL-12/GM-CSF therapy. Administration of CY mediated a significant delay in the post-IL-12/GM-CSF T-suppressor cell rebound resulting in a 7-fold increase in the CD8+ cytotoxic Tlymphocyte (CTL) to T-suppressor cell ratio, a 3-fold enhancement of CTL cytotoxicity and an extension of the effector window from 3 to 7 days. In long-term therapy studies, chronic chemoimmunotherapy promoted a dramatic enhancement of tumor regression resulting in complete cure in 44% of the mice receiving CY plus IL-12/GM-CSF. Tumor eradication in the chronic therapy setting was associated with the ability to repeatedly rescue and maintain cytotoxic CD8+ T-cell activity. These findings demonstrate that chronic administration of CY in conjunction with immune therapy not only enhances the initial induction of antitumor T-effector cells, but more importantly sustains their cytotoxic activity over the long-term via persistent blockade of homeostatic counter-regulation.
INTRODUCTION
Sustained delivery of IL-12 and GM-CSF to the tumor microenvironment restores cytotoxicity to tumor-resident CD8+ T-effector/memory (Tem) cells, eliminates pre-existing CD4+ CD25+ Foxp3+ T-suppressor cells and promotes the priming of a secondary CTL response in the tumor-draining lymph nodes (TDLN) [1] . However, T-effector cell activity is transient and is rapidly followed by a T-suppressor cell rebound resulting in pre-mature termination of antitumor cytotoxic activity (2, 3) . Repeated stimulation can rescue cytotoxic activity yet counter-regulation intensifies with each treatment ultimately resulting in the complete loss of the therapeutic effect (2) . The phenomenon of treatment-induced feedback inhibition is distinct from tumor-mediated immune suppression and represents a robust and persistent barrier to obtaining durable effector responses. Whereas the role of T-cell-intrinsic negative checkpoint molecules such as CTLA-4 and PD-1 in the regulation of T-effector cell activity has been studied extensively (4, 5) , the biology of post-stimulation regulatory cell resurgence is less-well characterized, particularly in the context of cancer immune therapy.
CD4+ CD25+ Foxp3+ T-suppressor cells either develop in the thymus (central) or are induced in the periphery (peripheral) from naïve precursors (6) . In tumors, both populations contribute to immune suppression but pre-existing central T-suppressors have been identified as the predominant source of post-therapy regulatory cell expansion (7, 8) . We therefore hypothesized that depletion of the tumor/TDLN-resident T-suppressor pool prior to IL-12/GM-CSF therapy could diminish treatment-induced regulatory rebound. Of the numerous T-suppressor cell depletion strategies that have been tested, use of chemotherapeutics stands out due to its efficacy and simplicity of use (9, 10) . Specifically, the ability of cytotoxic drugs to augment antitumor immune responses, a phenomenon that was reported more than four decades ago (11) , has been shown to involve several distinct mechanisms including the enhancement of tumor cell immunogenicity (10, 12) , the preferential depletion of regulatory cells (9, 10, 13) and the induction of a homeostatic recovery environment that is rich in growth-promoting cytokines (14) . Whereas the mechanisms underlying the synergistic activity of select chemotherapeutics on T-effector cell induction are well-understood, potential longer-term effects of these compounds on post-therapy regulatory rebound have not been investigated.
Among the numerous cytotoxic drugs that have been evaluated, CY has been consistently shown to synergize with immune therapy via its cytotoxic activity on T-suppressor cells (15) and more recently its pro-immunogenic effects on myeloid cells (16, 17) . Specifically, these studies demonstrated that a single bolus of CY administered prior to tumor vaccination potentiated both the initial effector T-cell priming and the long-term memory response (9, 10, 13, 15) . At the same time, whether administration of CY could also diminish the posttherapy T-suppressor cell rebound, which rapidly curbs the initial effector activation independent of its intensity, has not been tested. The potential impact of CY on the posttherapy regulatory surge is particularly relevant in the chronic treatment setting, as repeated immune stimulation leads to exacerbation of counter-regulation and the complete loss of the ability to rescue T-effector cell activity (2) . To this end, functional kinetics of intratumoral T-effector and T-suppressor cells as well as overall tumor growth were monitored in her-2/ neu transgenic FVBneuN mice following immunotherapy versus chemoimmunotherapy. The results demonstrate that administration of a single pulse of CY prior to IL-12/GM-CSF treatment not only resulted in effective depletion of tumor and TDLN-resident T-suppressors and enhanced effector T-cell activation, but also delayed the post-therapy rebound and extended the antitumor effector window. Importantly, chronic CY + IL-12/GM-CSF treatment repeatedly rescued antitumor CTL activity via persistent blockade of the Tsuppressor upsurge, ultimately resulting in the complete eradication of advanced spontaneous mammary tumors in a significant proportion of the mice.
MATERIALS AND METHODS

Mice
Breeding pairs of FVBneuN mice (FVB/N-TgN MMTVneu 202Mul) were obtained from Jackson Laboratories (Bar Harbor, Maine) and were maintained in our facility. Spontaneous mammary tumor development in female mice was monitored by weekly palpation of animals 18 weeks and older. Mice were used in studies when the primary tumor reached 100mm 3 -350 mm 3 . All studies were approved by the Institutional Animal Care and Use Committee at the State University of New York at Buffalo.
Cytokines and Microspheres
Recombinant murine IL-12 was a gift from Wyeth Pharmaceuticals. Recombinant murine GM-CSF was purchased from Peprotech. Phase inversion nanoencapsulation (PIN) technology was used to encapsulate IL-12 and GM-CSF in poly-lactic acid microspheres as previously described except at a cytokine loading of 0.025 % w/w (18) . Blank microspheres were used for control injections. Mice were injected intratumorally with 4 mg of each microsphere preparation (equivalent to 1 μg of each cytokine) suspended in 0.1 ml of sterile PBS.
Chemotherapy
Cyclophosphamide monohydrate, ISOPAC was purchased from Sigma-Aldrich (St Louis, MO). Mouse weight was determined and 200 mg/kg of cyclophosphamide (dissolved in sterile PBS) was injected intraperitoneally. When combined with microsphere treatment, chemotherapy was administered 24 hours prior to IL-12/GM-CSF microspheres.
Monitoring of Survival and Tumor Growth
Tumor size was measured weekly. Two separate diameter measurements of the tumor were recorded using calipers and the tumor volume was determine by the following formula (A × B 2 )/2 = volume (A = longest tumor diameter, B = smaller perpendicular tumor diameter). Mice were sacrificed when the longest diameter of the primary tumor reached 15 mm or when the total of the largest diameters of multiple tumors reached 15 mm.
Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR) was performed as previously described (19) . Briefly, total RNA was isolated from tissue samples using TRIzol and was reversetranscribed with TaqMan kit (Applied Biosystems). Real-time PCR analysis was performed with the primers listed below and iQ SybrGreen Supermix (BioRad) using the recommended cycling conditions (denaturation at 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds and 72°C for 30 seconds). Transcript levels were calculated by the comparative threshold cycle (C t ) method (20) . The relative target quantity was normalized to an endogenous control (β-actin) to generate the ΔC t. The ΔΔC t was determined as the ΔC t of samples for the target gene minus the ΔCt of the untreated calibrator for the target gene. Fold change in mRNA level was defined as 2 −ΔΔCT . The primer sequences were: CD8, 5′-GCT ACC ACA GGA GCC GAA AG -3′ (forward) and 5′-TGG GCT TGC CTT CCT GTC T -3′ (reverse); Granzyme B, 5′-ATC AAG GAT CAG CAG CCT GA-3′ (forward) and 5′-TGA TGT CAT TGG AGA ATG TCT-3′ (reverse); IFNγ, 5′-GGC ACA GTC ATT GAA AGC-3′ (forward) and 5′-TGC CAG TTC CTC CAG ATA-3′ (reverse); β-actin, 5′-TCA CCC ACA CTG GCC CAT CTA CGA-3′ (forward) and 5′-TGG TGA AGC TGT AGC CAC GCT-3′ (reverse).
Preparation of single cell suspensions from tumor and TDLN
Tumors were minced into small pieces (1-2mm 3 ) and subjected to enzymatic digestion as previously described (2) on a rotating platform for 80 minutes. The sample was suspended in serum-free media and passed though a 70 μm cell strainer (Fischer Scientific), and enriched for lymphocytes by gradient separation using Lympholyte-M (Cedar Lane) according to the manufacturer's protocol. Lymph nodes were crushed between frosted glass slides and collected in DMEM/F12 and 5% FBS. The lymph node sample was passed through a 40 μm cell strainer (Fischer Scientific) to obtain a single cell suspension.
BrdU Injections
Bromodeoxyuridine (1 mg), obtained from the BD Pharmigen BrdU flow kit, was injected intraperitoneally three hours before sacrifice (3).
Flow cytometry and intracellular staining
Cells were stained with fluorochrome-conjugated antibodies according to manufacturer's protocols and analyzed on a four-color FACScalibur flow cytometer (Becton-Dickinson). The following antibodies were purchased from BD Pharmingen: FITC-anti-CD8 (53-6.7), FITC-anti-CD4 (GK1.5), APC-anti-CD4 (RM4-5), PerCP-anti-CD45 (30-F11). Intracellular staining for Foxp3 (PE-anti-Foxp3 antibody, NRRF30) was performed using a kit for detection (ebioscience) according to the manufacturer's directions. Intracellular staining for BrdU detection was also performed according to manufacturer's instructions (BD Pharmingen, APC-anti-BrDU, 3D4). When Foxp3 and BrdU intracellular staining were combined, the BrdU BD Pharmingen kit instructions were followed in their entirety followed by incubation with the anti-Foxp3 antibody.
In vivo cell depletions
NK cells and CD8+ T cells were depleted according to previously published methods (19) . For depletion of CD25+ cells, mice were injected with the anti-CD25 antibody PC615.3 (Bio-X-Cell) intraperitoneally (1 mg in 0.2 ml PBS) 2 days prior to cytokine treatment.
Tumor challenge studies
Mice bearing single established primary tumors (100-300 mm 3 ) were left untreated or received a single cycle of immunotherapy or chemoimmunotherapy. Three weeks later animals were injected subcutaneously with the syngeneic LAP0297 lung tumor cell line (a kind gift from Dr. Peigen Huang, Harvard University) and the her-2 expressing NT2.5 mammary tumor cell line (kindly provided by Dr. Elizabeth Jaffee, Johns Hopkins University) in opposite flanks (2 × 10 6 cells in 0.1 ml saline, sc). Tumor volume was monitored as described above.
Statistical analysis
Student's t-test was used to determine the significance of the differences between control and experimental groups in pairwise comparisons. In experiments with multiple groups homogeneity of inter-group variance was analyzed by ANOVA. Log-Rank analysis was employed to determine significance in survival studies. In all analyses p ≤ 0.05 was considered significant.
RESULTS
Administration of CY prior to IL-12 + GM-CSF treatment delays post-therapy T-suppressor cell rebound and enhances both the intensity and the duration of the cytotoxic effector window
The mammary tumors that spontaneously arise in her-2/neu transgenic FVBneuN mice display a chronic slow-growing phenotype yet are highly resistant to immune therapy (21) (22) (23) (24) . Previous studies in our laboratory showed that a single intratumoral injection of slowrelease IL-12 and GM-CSF formulations resulted in T-cell dependent regression of established tumors in this model (25) . The antitumor effect however, was transient and tumors resumed growth after several weeks (25) . Further analysis revealed that tumor resurgence was associated with a dramatic expansion of T-suppressor cells (2) . Figure 1A displays the cellular kinetics of CD8+ T-effector and CD4+ Foxp3+ T-suppressor cells in post-therapy tumors, demonstrating the rapid and potent nature of counter-regulation. We hypothesized that elimination of pre-existing CD4+ Foxp3+ T-cells cells prior to treatment could delay treatment-associated regulatory surge. The ability of CY to preferentially deplete regulatory cells is well-known and is thought to be associated with the higher rate of turnover these cells exhibit in the steady-state tumor. Figure 1B shows that both TDLN and intratumoral T-suppressors proliferated at a significantly higher rate than CD8+ or CD4+ Teffectors. Administration of CY on the other hand, resulted in a rapid and significant drop in both the CD4+ Foxp3+ to CD8+ T-cell and CD4+ Foxp3+ to CD4+ Foxp3-T-cell ratios on day 3, which remained low until day 8 ( Figure 1C ) suggesting that this strategy could be effective in blocking post-therapy T-suppressor cell expansion.
To directly test the above hypothesis, mice were administered CY one day prior to cytokine treatment and intratumoral CD8+ T-effector vs CD4+ Foxp3+ T-suppressor cell kinetics were monitored. The results are shown in Figure 2 . Chemoimmunotherapy had a significant effect on both the effector and the suppressor T-cell kinetics (Figure 2A ). CD8+ T-cell expansion in mice receiving CY was delayed but ultimately enhanced. Importantly, CD8+ T-cells continued to proliferate between days 3 and 7 in the CY + IL-12/GM-CSF group whereas proliferation peaked on day 3 but returned to background levels on day 7 in the immunotherapy group. Conversely, chemoimmunotherapy resulted in a 4-fold decrease in CD4+ Foxp3+ T-cells on day 3 versus a 6-fold increase in T-suppressors in mice receiving immunotherapy alone ( Figure 2C ). CY-mediated reduction in T-suppressor cell numbers on day 3 however, was short-lived and the cells recovered rapidly between days 3 and 7 reaching levels that were observed in the immune therapy alone group.
The ratio of proliferating CD8+ T-cells to CD4+ Foxp3+ T-cells in the tumor, i.e. the activity index, is highly predictive of therapeutic efficacy (3) . To this end, monitoring of the activity index in mice receiving chemoimmunotherapy revealed that effector activity increased nearly 5-fold between days 0 and 3 but declined rapidly thereafter, reflecting the rapid recovery of T-suppressor cells between days 3 and 7 ( Figure 2B ). In contrast, in the immune therapy alone group activity index remained unchanged between days 0 to 3 and declined to below pre-therapy levels on day 7 demonstrating the potent neutralizing effect of the T-suppressor cell expansion ( Figure 2B ). The advantage chemoimmunotherapy provides is best displayed in Figure 2C where the fold-differences between the activity indices of the two groups are displayed. These data demonstrate that CY enhanced the activity index by 4-fold on day 3 and by 7-fold on day 7 with the ratio returning to background levels on day 14. The above findings establish that chemotherapy not only delayed the T-suppressor cell rebound but also enhanced the intensity and the duration of the effector window.
Chronic chemoimmunotherapy achieves complete cure of advanced spontaneous mammary tumors Earlier studies in the FVBneuN mice had shown that repeated treatment could revive effector activity but that the intensification of T-suppressor cell resurgence with each cycle of treatment ultimately led to loss of therapeutic benefit (2) . To this end, we next tested the hypothesis that chronic chemoimmunotherapy could maintain the activity of antitumor CD8+ T-effectors and achieve superior tumor eradication in the long-term. Mice with established spontaneous mammary tumors were treated with control particles, CY-alone, IL-12/GM-CSF particles or CY + IL-12/GM-CSF particles every 3 weeks for 3 cycles and tumor growth was monitored. Tumor growth patterns of individual mice in different groups are shown in Figure 3A . These data reveal that tumors grew progressively in the control mice and all but one mouse had to be euthanized by week 9. Treatment with CY alone caused a slight delay but all tumors maintained growth. IL-12/GM-CSF therapy achieved longer-term suppression with tumors regressing completely in 2 of 11 mice during therapy however both tumors recurred by week 9. In contrast, 7 of 9 tumors either regressed or were growth-arrested for the duration of the study in the chemoimmunotherapy group with complete long-term cure in 4 of 7 responders. The overall survival patterns are shown in Figure 3B . In the chemoimmunotherapy group all mice remained alive at week nine. In contrast, 9-week survival was 72%, 55% and 10% in immune therapy, CY-alone and control groups, respectively. All remaining mice in these groups were euthanized between weeks 9 and 10 either due to continued primary tumor growth or the development of independent secondary tumors. Of the 4 "cured" mice in the chemoimmunotherapy group, the primary tumor recurred in one mouse at week 12 while the other 3 remained tumor-free for 3 months at which point they were euthanized. Separately, immune therapy alone failed to suppress the development of secondary tumors but CY-alone or CY + IL-12/GM-CSF had a substantial impact on the appearance of independent tumors ( Figure 3C ). Collectively, these results establish that chemoimmunotherapy was highly effective in the chronic treatment setting.
Curative effect of chronic therapy is associated with maintenance of CD8+ T-cell cytotoxicity Whereas the data shown in Figure 3 confirmed the long-term efficacy of the combination strategy, whether this effect was due to enhanced CD8+ T-cell activity or was associated with T-cell-independent effects of CY was not clear. To this end, T-cell cytotoxicity markers were monitored in post-therapy tumors. The expression levels of CD8, IFNγ and Granzyme B mRNA were monitored on day 3 post-treatment in the control, immune therapy and chemoimmunotherapy groups. Immune therapy alone induced increases in both IFNγ (30-fold) and Granzyme B (2-fold) levels when normalized to CD8-expression ( Figure 4A ). Chemoimmunotherapy on the other hand resulted in significantly superior cytotoxic activity with 80-and 6-fold increases in IFNγ and Granzyme B, respectively ( Figure 4A ). These increases were primarily associated with CD8+ T-cell activation as depletion of CD8+ T-cells prior to treatment resulted in the near complete loss of post-therapy cytotoxicity ( Figure 4B ).
The results above established an empirical link between preferential T-suppressor cell depletion and enhanced CD8+ T-cell activity. However, CY can promote CTL cytotoxicity via other mechanisms including the induction of a homeostatic recovery environment (14) , the abrogation of TAM or MDSC suppressive function (16, 17) , and/or the promotion of myeloid cell inflammatory activity (26, 27) . To this end, we tested a more targeted depletion strategy involving the use of anti-CD25 antibody, which selectively eliminates pre-existing CD4+ CD25+ T-suppressor cells when administered prior to T-effector activation (28) . Analysis of the activity index as well as tumor growth in mice treated with the anti-CD25 antibody versus CY demonstrated that both strategies were equally effective in enhancing tumor suppression confirming the direct link between T-suppressor cell elimination and enhanced antitumor cytotoxicity (Supplemental Figure 1) . Separately, we also found that the non-specific pro-inflammatory activity of CY (26, 27) was not a contributing factor as addition of CY to IL-12/GM-CSF treatment did not enhance IL-1β production, a marker of CY-mediated inflammation (data not shown). Collectively, these findings strongly support the notion that the beneficial effects of CY on CTL activity were predominantly associated with the depletion of the pre-existing T-suppressor cell pool in our model.
Previous studies in FVBneuN mice demonstrated only a partial role for CD8+ T-cells in IL-12/GM-CSF-mediated tumor regression (25) . In addition, a rapid but transient activation of NK-cells was also found to be critical to post-IL-12/GM-CSF tumor kill (19) . Since the above data revealed a significant enhancement of CD8+ T-cell cytotoxicity by CY, in vivo antibody depletions were performed to determine the respective roles of CD8+ T-and NKcell subsets in CY + IL-12/GM-CSF-mediated tumor cure. The results are shown in Figure  4C . Immune therapy alone resulted in moderate suppression of tumor growth. Depletion of CD8+ T-cells did not significantly impact tumor suppression suggesting that CD8+ T-cells did not play a major role in tumor kill following treatment with IL-12 + GM-CSF alone. Depletion of the NK-cells on the other hand resulted in a significant loss (~50%) of tumor suppression. As expected, chemoimmunotherapy resulted in a dramatic enhancement of tumor suppression. In contrast to what was observed with immune therapy alone however, depletion of CD8+ T-cells completely nullified the CY-mediated increase in antitumor activity. The augmentation of CTL cytotoxicity by CY was not due to direct stimulation of CD8+ T-cells as depletion of CD8+ T-cells in mice receiving CY-alone did not adversely affect the transient antitumor activity of CY (data not shown). Moreover, depletion of NKcells in these mice still resulted in potent tumor suppression identifying CD8+ T-cells as the primary antitumor effectors in this setting. These data establish that the synergistic activity of CY was strictly associated with the restoration of CD8+ T-cell-mediated tumor kill.
Whereas these findings established the critical role of CD8+ T-cell activation in chemoimmunotherapy-mediated tumor kill, whether this activity resulted in the development of long-term protective memory was not determined. To address this question, FVBneuN mice bearing single established spontaneous tumors were treated either with IL-12/GM-CSF or CY + IL-12/GM-CSF and were then challenged with a her-2-expressing FVBneuN mammary tumor cell line (NT2.5) and a syngeneic control lung tumor cell line (LAP0297). The mice were then monitored for tumor growth. The data shown in Table 1 establish that treatment of the primary tumor prior to challenge resulted in the development of a tumor-specific response that effectively suppressed the growth of the syngeneic FVBneuN mammary tumor cell line but not that of the lung tumor cell line (the somewhat slower growth of the lung tumor in the treated mice was not significantly different from that observed in the control mice). Furthermore, the protection afforded by chemoimmunotherapy was highly superior to that induced by immune therapy alone.
To determine whether CD8+ T-cell activity was maintained during repeated treatment, quantitative and qualitative changes in CD8+ T-cell and CD4+ Foxp3+ T-suppressor cells were monitored in mice receiving multiple treatments. Tumors were analyzed 3 days after the third treatment since previous analyses had revealed that the activity index peaked on day 3 post-therapy (Figure 2 ). Both CD8+ T-cell and CD4+ Foxp3+ T-cell numbers increased by 4 to 6-fold on average in mice treated with immune therapy alone similar to that seen following the first treatment ( Figure 5A ). In contrast, CD8+ T-cell numbers remained unchanged while the CD4+ Foxp3+ T-cell numbers decreased by an average of 3-fold after the third treatment, again replicating the pattern observed after the first treatment. Moreover, chemoimmunotherapy again enhanced both the CD8+ T-cell proliferation and the activity index ( Figure 5B ). Finally, chemoimmunotherapy induced a 2 to 3-fold increase in CD8+ T-cell cytotoxicity markers in comparison to immune therapy alone ( Figure 5C ). These data establish that chronic therapy repeatedly rescued T-effector cell activity during the 6 week therapeutic window, although the overall enhancement diminished after the third cycle.
DISCUSSION
Our data demonstrate that administration of a single pulse of CY prior to IL-12/GM-CSF therapy promoted complete cure of advanced spontaneous mammary tumors in FVBneuN mice, a model in which therapeutic success has been limited to either the preventive setting (21) (22) (23) (24) or to treatment of transplanted syngeneic tumor cell lines (29) (30) (31) (32) . The potentiation of tumor kill was directly associated with the depletion of the pre-existing T-suppressor cell pool resulting in a transient delay in post-therapy T-suppressor cell expansion and an extended cytotoxic window. Importantly, this approach allowed repeated rescue of CD8+ Tcell cytotoxicity leading to long-term benefit. This is in contrast to earlier studies in which the intensification of the counter-regulatory response during chronic treatment with IL-12/ GM-CSF particles culminated in the complete loss of antitumor CTL activity (2).
Previous work had established that IL-12/GM-CSF treatment could induce tumor-specific CTL in FVBneuN mice, which could effectively kill autochthonous mammary tumors in culture (2, 25) . At the same time antibody-mediated subset depletion studies suggested a modest role for CD8+ T-cells in treatment-induced tumor regression in vivo (25) . These findings led to the hypothesis that failure of post-treatment CTL to mediate successful tumor regression in vivo was likely associated with the concurrent expansion of CD4+ CD25+ Foxp3+ T-suppressor cells (2) . The current findings support this notion as transient neutralization of the regulatory rebound resulted in the restoration of CD8+ T-cell mediated tumor kill demonstrating the critical role of these cells in long-term tumor eradication. The finding that NK-cells could mediate effective tumor suppression independent of posttherapy T-suppressor cell expansion in earlier studies was likely associated with the rapid kinetics of post-IL-12 NK-cell activation in the tumor (19) , which precedes post-treatment CD8+ T-cell priming (33) and T-suppressor cell expansion (3). Analysis of latent tumor development in post-therapy mice revealed that primary and secondary tumors responded differently to treatment. Specifically, whereas immunotherapy was critical to suppression of primary tumors, secondary tumors were suppressed in CY-alone or CY+IL-12/GM-CSF groups but not in the IL-12/GM-CSF-alone group. Systemic suppression of treatmentinduced CTL by expanding T-suppressors in mice receiving immune therapy alone could explain this observation. Alternatively, since multi-focal tumors arise independently in FVBneuN mice, the CTL that are induced against the treated tumor may not be effective against secondary tumors with different immunogenic profiles (34) . Separately, suppression of secondary tumors by CY could be due to its immune-independent cytotoxic effects or to its ability to enhance concomitant immunity (35) , particularly since the latent tumor burden was minimal, i.e. non-papable, at the time of the initial treatment. Whether the observed differences are due to one or a combination of the above remain to be determined.
A direct comparison of the intensities of post-therapy CD8+ T-cell activity after the first and third treatments revealed that while the elimination of pre-existing T-suppressors allowed repeated rescue of T-effector activity, overall cytotoxicity diminished with additional treatment. It is well-known that chronic exposure to antigen can result in the anergy or deletion of effector T-cells (36, 37) . Moreover, the preferential effects of CY on Tsuppressor cells are not absolute and collateral CD8+ T-cell loss cannot be avoided (38) . Whether the progressive loss of CTL cytotoxicity is associated with T-cell intrinsic exhaustion/deletion mechanisms, CY-mediated cumulative loss of antitumor CD8 T-cells or a combination of both was not determined here. Preliminary quantification of CTLA-4, PD-1 or CEACAM-1 on tumor-infiltrating CD8+ T-cells demonstrated a 2 to 3-fold increase in membrane expression after the first treatment cycle; however additional treatments failed to induce further change (Harden JL and Egilmez NK, unpublished observations) suggesting that T-cell intrinsic negative checkpoint mechanisms did not play a major role in the longterm loss of T-cell cytotoxicity. Regardless of the underlying mechanism, our findings suggest that even when post-therapy regulation is blocked, progressive contraction of the Teffector cell pool during chronic treatment may ultimately limit the long-term utility of immunotherapy in the management of tumors that persist.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Mice treated with CY+IL-12/GM-CSF or IL-12/GM-CSF alone were sacrificed 3, 7 and 14 days after microsphere injection and tumor-infiltrating T-cell populations were analyzed. Panel A. CD8+ T cells or T-suppressor cells were quantified and normalized to Day 0 (CD8+ T-cells) or to Day -1 (T-suppressor cells) to determine fold-changes in total CD8+ T-cell or CD4+Foxp3+ T cell numbers and percent proliferating CD8+ T-cells. Immunotherapy resulted in increased CD8+ T-cell numbers on day 3 (p = 0.01) whereas chemoimmunotherapy enhanced CD8+ T-cell numbers on day 7 (p = 0.03) compared to day 0. The differences between the 2 treatment groups were significant on days 3 and 7 (p ≤ Panel A. CY augments post-therapy cytotoxicity. IFNγ and Granzyme B mRNAs were quantified by real-time PCR prior to and 3 days post-microsphere treatment and normalized to CD8 mRNA. The differences between the chemoimmunotherapy group and immune therapy alone or control groups were significant both for IFNγ and Granzyme B (p ≤ 0.02, n = 8-9 per group). Panel B. CY-mediated enhancement of cytotoxicity is dependent on CD8+ T-cells. The effect of CD8+ T-cell depletion on IFNγ and Granzyme B expression was determined. The pair-wise differences between the CD8+ T-cell depleted experimental and non-depleted control groups were significant (p ≤ 0.02, n = 3-6 per group). Panel C. Chemoimmunotherapy restores CD8+ T-cell-mediated tumor kill. Mice were depleted of CD8+ T or NK-cells prior to treatment as described in the Methods. Fold-change in tumor volume was determined 3 weeks post-microsphere injection. Fold-change in tumor volume in all treatment groups was significant compared to control (p ≤ 0.002, n = 6-14 per group in the CD8 depletion study and n = 5-14 per group in the NK-cell depletion study). Error bars = SE. The overall pattern of tumor growth remained essentially identical when actual tumor volumes were plotted (Supplemental Figure 2) . Mice were treated every 3 weeks for a total of 3 treatments (microsphere injections on days 0, 21 and 42). Tumors were analyzed 3 days after the third treatment (day 45). Fold-changes for each parameter shown were determined via comparison of day 45 tumors to control tumors obtained from mice that received 2 treatments but were euthanized just prior to the third microsphere treatment. Each point represents an individual mouse. Panel A. Repeated treatment maintains preferential T-suppressor cell depletion. The differences between the immune therapy and chemoimmunotherapy groups were significant both for CD8+ and CD4+ Foxp3+ T-cells (p = 0.01 and 0.05, respectively). Panel B. CD8+ T-cell activation is preserved during chronic therapy. CD8+ T-cell proliferation and the activity index were analyzed after the third treatment. The differences between immune therapy and
